Clinical Trials Logo

Syndrome clinical trials

View clinical trials related to Syndrome.

Filter by:

NCT ID: NCT03755414 Active, not recruiting - Clinical trials for Myelodysplastic Syndromes

Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation

Start date: September 4, 2019
Phase: Phase 1
Study type: Interventional

In this trial, the investigators will begin to explore the possibility that, as in mice, janus kinase inhibitor 1 (JAK1) inhibition with haploidentical-hematopoietic cell transplantation (HCT) may mitigate graft-versus-host-disease (GVHD) and cytokine release syndrome (CRS) while retaining Graft-versus-Leukemia (GVL) and improving engraftment. The purpose of this pilot study is to determine the safety of itacitinib with haplo-hematopoietic cell transplantation (HCT) measured by the effect on engraftment and grade III-IV GVHD.

NCT ID: NCT03752619 Active, not recruiting - Shoulder Pain Clinical Trials

Peripheral Nerve Stimulation(PNS) for Subacromial Impingement Syndrome(SIS)

Start date: March 1, 2019
Phase: N/A
Study type: Interventional

Shoulder pain accounts for 16% of all musculoskeletal complaints in the healthy adult population. Subacromial impingement syndrome (SIS) is the most common cause of shoulder pain. Many patients with chronic pain from subacromial impingement syndrome (SIS) will fail treatment efforts and have longstanding pain. This project will evaluate the efficacy of a novel approach to treatment, percutaneous peripheral nerve stimulation, for participants with chronic shoulder pain due to subacromial impingement syndrome (SIS).

NCT ID: NCT03752515 Active, not recruiting - Clinical trials for Coronary Artery Disease

A Registry Study on Genetics and Biomarkers of Acute Coronary Syndrome

ARSGB-ACS
Start date: June 2, 2015
Phase:
Study type: Observational

This is a national registry study to determine genetics risk factors and serial biomarkers of Acute Coronary Syndrome.

NCT ID: NCT03748602 Active, not recruiting - Clinical trials for Neurogenic Thoracic Outlet Syndrome

Surgical Thoracic Outlet Decompression for Neurogenic Thoracic Outlet Syndrome

STOPNTOS
Start date: October 1, 2018
Phase: N/A
Study type: Interventional

This study will determine the value of TOD (first rib resection with partial scalenectomy and neurolysis) on functionality and quality of life for patients with neurogenic thoracic outlet syndrome. This will be done by randomizing patients into surgery or conservative therapy (physiotherapy and pain relief).

NCT ID: NCT03744390 Active, not recruiting - Clinical trials for Myelodysplastic Syndromes

IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome

Start date: April 2, 2019
Phase: Phase 2
Study type: Interventional

patients with MDS (Myelodysplastic Syndrome) and mutated IDH2 patients will be treated with AG221 (IDH2 inhibitor)

NCT ID: NCT03741790 Active, not recruiting - Clinical trials for Klippel-Feil Syndrome

Airway Management of Pediatric Patients With Klippel-Feil Syndrome

Start date: November 1, 2018
Phase:
Study type: Observational

Klippel-Feil syndrome (KFS) was first described in 1912 by Klippel and Feil as a classic triad are comprised of a short neck, a low posterior hairline and restricted motion of the neck. This disease is considered as one of the congenital causes of difficult airway with the incidence of 1:42,000 live births. The current research findings suggested that the difficulties of airway management for KFS increases with age. In pediatric patients, the airway of those patients can be managed without difficulties. For adults, the fiberoptic-assisted intubation is also suggested. The purpose of this study is to review the airway management of pediatric patients with KFS to provide recommendation of airway management for these patients. A retrospective electronic chart review will be conducted by using Boston Children's Hospital (BCH) database, which identified patients with KFS who had undergone general anesthesia from June 2012 to June 2018.

NCT ID: NCT03738774 Active, not recruiting - Clinical trials for Post Intensive Care Syndrome

Addressing Post-Intensive Care Syndrome Among Survivors of COVID (APICS-COVID)

APICS
Start date: January 2, 2019
Phase:
Study type: Observational

This study will assess the relationship between early unmet needs after hospital discharge and subsequent clinical outcomes among survivors of acute respiratory failure. The investigators hypothesize that early unmet needs are associated with poor outcomes at three months.

NCT ID: NCT03736174 Active, not recruiting - Clinical trials for Chronic Exertional Compartment Syndrome

Utilization of High Frequency Ultrasound to Diagnose Chronic Exertional Compartment Syndrome

Start date: December 7, 2018
Phase:
Study type: Observational

The purpose of this study is to investigate high frequency ultrasound as a future modality for the diagnosis of chronic exertional compartment syndrome (CECS). The results of the ultrasound will help determine if there are any significant radiologic findings or patterns seen in patients with CECS.

NCT ID: NCT03717909 Active, not recruiting - Wolfram Syndrome Clinical Trials

Efficacy and Safety Trial of Sodium Valproate, in Paediatric and Adult Patients With Wolfram Syndrome

Start date: December 28, 2018
Phase: Phase 2
Study type: Interventional

This trial aims to investigate the efficacy, safety and tolerability of sodium valproate in the treatment of patients with Wolfram syndrome. 70 paediatric and adult patients were initially planned to be randomised 2:1 to receive either sodium valproate or placebo at 6 international centres. 63 patients were recruited when a decision was made to stop the study recruitment in November 2022.

NCT ID: NCT03711214 Active, not recruiting - Sjogren's Syndrome Clinical Trials

Immune Profile of Saliva and Serum of Patients With Primary Sjögren´s Syndrome

pSS
Start date: December 1, 2018
Phase: N/A
Study type: Interventional

Primary Sjögren's syndrome (pSS) is a chronic systemic inflammatory disease, which mainly affects the lacrimal and salivary glands, leading to sicca syndrome. pSS has a probable autoimmune etiology, with the production of several autoantibodies such as antinuclear antibodies (ANA), anti-Ro/SS-A, anti-La/SS-B, rheumatoid factor (RF) and cryoglobulins. Recently, our group described a high frequency of antibodies directed to DNase I in the serum of pSS patients and these antibodies were associated with the presence of the anti-Epstein-Barr (EBV) early antigen diffuse (anti-EA-D). This finding becomes interesting considering the recent description of reduction of DNase I activity in the tear of patients with xerophthalmia of different causes, which would result in an accumulation of extracellular DNA and neutrophilic inflammatory infiltrate on the ocular surface. This hypothesis is reinforced by the observation that treatment with DNase I as eye drops results in clinical improvement of dry eye. In addition, it has been shown that periodontal disease is an aggravating factor of xerostomia in pSS, as it leads to a chronic inflammatory process and, consequently, to the destruction of minor salivary glands. Therefore, the objective of the present study will be to evaluate the presence of antibodies directed to DNase I in the saliva and serum of pSS patients and its possible capacity of inhibition of the enzyme before and after treatment of periodontal disease. Such findings will be correlated with the presence of periodontal disease, with the glandular and extraglandular manifestations of SSp and also with the presence of EBV DNA in the serum and oral lavage of these patients.